Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs is a clinical-stage biotechnology company with a positive outlook due to its diversified vaccine portfolio for diseases such as smallpox and COVID-19. With multiple key catalysts approaching, including the planned Phase 3 immunobridging study for GEO-MVA in late 2026 and potential data in 2027, and the advancement of the Gedeptin checkpoint inhibitor combination strategy in oncology, the company has significant potential for long-term growth. However, the stock is unlikely to see near-term share price support due to the longer timeline for value realization. Additionally, while the company's AGE1 manufacturing platform solves supply constraints, its constrained balance sheet may require additional dilution to fund ongoing clinical development and working capital needs.

Bears say

Geovax Labs is facing a constrained near-term outlook due to limited catalysts and tightening capital resources, prompting analyst expectations to be lowered from Buy to Hold. The company's strategic focus on advancing GEO-MVA, its mpox/smallpox vaccine candidate, shows potential but the balance sheet remains a key limiting factor. The completed $1M registered direct offering highlights financing challenges, indicating a likelihood of additional dilutive capital raises. The company reported a decline in revenue and improved net loss for 2025, with a decrease in R&D expenses but an increase in G&A expenses. With low liquidity at the end of 2025, external funding will likely be necessary to fully execute on their late-stage development plans.

Geovax Labs (GOVX) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Hold based on their latest research and market trends.

According to 1 analysts, Geovax Labs (GOVX) has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.